Meta Held Deal Talks With Startup Runway in AI Recruiting Push
Meta Platforms Inc. Chief Executive Officer Mark Zuckerberg discussed a possible acquisition with video startup Runway AI Inc., as part of his deal-making drive in artificial intelligence.
The deal talks never reached a formal offer level where a dollar figure was discussed, and are no longer ongoing, according to people familiar with the matter, who asked not to be identified because they weren't authorized to speak about it. Zuckerberg has been on a hunt for the best minds in AI to build a 'superintelligence' team — a recruitment push that has involved high salary offers and sometimes deal talks with targets. The company recently finalized a multibillion-dollar investment in Scale AI.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
7 minutes ago
- Washington Post
Federal court says copyrighted books are fair use for AI training
A federal judge this week ruled that artificial intelligence company Anthropic did not break the law when it used copyrighted books to train its chatbot, Claude, without the consent of the texts' authors or publishers — but he ordered the company to go to trial for allegedly using pirated versions of the books. The decision, made Monday by Judge William Alsup of the U.S. District Court for the Northern District of California, represents a win for AI companies, which have battled copyright lawsuits from writers and news organizations for using their work to train AI systems. Alsup said Anthropic's use of the books to train its large language models, was like an aspiring writer who reads copyrighted texts 'not to race ahead and replicate or supplant' those works, 'but to turn a hard corner and create something different.' His ruling was on a lawsuit filed against Anthropic last year by three authors — Andrea Bartz, Charles Graeber and Kirk Wallace Johnson — who alleged that the company used their work without their consent to train AI systems in what amounted to 'largescale theft.' But Alsup ordered Anthropic to face trial for the accusation that it knowingly obtained copies of more than 7 million books from piracy websites, although the company later paid to purchase copies of some books. Alsup said he doubted that 'any accused infringer could ever meet its burden of explaining why downloading source copies from pirate sites that it could have purchased or otherwise accessed lawfully was itself reasonably necessary to any subsequent fair use.' 'That Anthropic later bought a copy of a book it earlier stole off the internet will not absolve it of liability for the theft but it may affect the extent of statutory damages,' he added. In a statement, Anthropic said it was pleased that the court recognized that using published works to train LLMs was consistent with copyright laws 'in enabling creativity and fostering scientific progress.' But the company said it disagrees with the decision to hold a trial for its 'acquisition of a subset of books and how they were used,' in apparent reference to the piracy allegations. 'We remain confident in our overall case, and are evaluating all options,' it said. In their lawsuit, the authors said the actions of Anthropic have made 'a mockery of its lofty goals.' The company was founded in 2021 by a group that included OpenAI's former vice president of research Dario Amodei with goals that included 'research into increasing the safety of AI systems.' Bartz and Johnson did not reply to requests for comment. Graeber declined to comment. After concerns arose within the company about using pirated books, Anthropic hired former Google Books executive Tom Turvey to obtain 'all the books in the world' while also avoiding as many legal issues as possible, according to court documents. Turvey and his team could have sought to reach commercial agreements with publishers to license the books to train its AI systems, Alsup noted, but they instead purchased millions of print books from retailers, many of them in used condition, then scanned them into digital form. The company could have also hired staff writers and engineers to create good original writing to train AI models. But that would have 'required spending more,' Alsup noted.
Yahoo
8 minutes ago
- Yahoo
Is J. M. Smucker Stock Underperforming the S&P 500?
With a market cap of $10.4 billion, The J. M. Smucker Company (SJM) produces a wide range of branded food and beverage products for global markets. Based in Orrville, Ohio, the company operates through several segments, including U.S. Retail Coffee, U.S. Retail Frozen Handheld and Spreads, U.S. Retail Pet Foods, and Sweet Baked Snacks. Companies with a market value of $10 billion or more are classified as 'large-cap stocks,' and SJM is a prominent member of this category. Its portfolio of well-established, trusted brands across multiple food and beverage categories, including coffee, pet food, spreads, and snacks, fuels its market leadership. Additionally, the company's strategic acquisitions and supply chain efficiencies support long-term growth and operational stability. Super Micro Computer Just Struck a Deal with Ericsson. Should You Buy SMCI Stock Here? CEO Jensen Huang Just Sold Nvidia Stock. Should You? Cathie Wood Is Dumping Circle Stock. Should You? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. However, SJM has been trading 22.5% below its 52-week high of $125.42, met on Nov. 26, last year. However, the stock has dipped 13% over the three months, underperforming the S&P 500 Index's ($SPX) 6.5% uptick during the same time frame. On a YTD basis, SJM has declined 11.7%, underperforming $SPX's 3.6% decline. Over the past year, SJM has declined 13.1%, underperforming $SPX's 11.8% rise over the same period. The stock has been trading below its 50-day and 200-day moving averages since early May, reinforcing a downtrend. J.M. Smucker shares dropped 13% in the second week of June, as of June 12, following weak fiscal Q4 results that saw sales and adjusted EPS decline by 3% and 13% to $2.1 billion and $2.31, respectively. Investor sentiment was further dampened by a $980 million impairment charge tied to its $5.6 billion Hostess Brands acquisition, bringing total write-downs on the deal to $2 billion, an indication that the company may have substantially overpaid for the purchase. Its peer, Hormel Foods Corporation (HRL), has dropped 3.1% in 2025 and 1.8% over the past 52 weeks, notably outperforming SJM. SJM has a consensus rating of 'Moderate Buy' from 16 analysts covering it. Its mean price target of $111.67 indicates a modest 14.9% upside potential from the current market price. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Business Insider
14 minutes ago
- Business Insider
Why Is Nektar Therapeutics Stock (NKTR) Up 110% Today?
Nektar Therapeutics (NKTR) stock surged on Tuesday after the California-based biopharmaceutical company announced results from its Phase 2b study of rezpegaldesleukin. This is a treatment in development for patients with eczema. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Results from the clinical trial were positive, with the primary endpoint met. On top of that, all of the study's secondary endpoints were also achieved. Nektar Therapeutics will continue treatment of patients in this study, with topline results expected in Q4 2025 and additional data in Q1 2026. Nektar Therapeutics stock soared 110.17% on Tuesday alongside its clinical trial results. That builds on a 12.1% rally yesterday. However, the shares are still down 31.61% year-to-date and 40.56% over the past 12 months. Is Nektar Therapeutics Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Nektar Therapeutics is Strong Buy, based on four Buy and one Hold rating over the past three months. With that comes an average NKTR stock price target of $73.13, representing a potential 666.56% upside for the shares.
